Nanoview Biosciences

The company's business revolves around providing advanced tools for life science researchers working with biologics and gene therapy. Its client base primarily consists of research laboratories, early-stage biotech companies, and academic institutions that require specialized EV analysis. Nanoview Biosciences generated revenue through the sale of its proprietary platforms and associated consumables to these clients. In May 2022, the company was acquired by Unchained Labs, a life sciences tools company, for an undisclosed amount.

The core product offering is the ExoView platform, a system designed to fully characterize exosomes and other extracellular vesicles. The first product, the ExoView R100, launched in 2019, provided high-resolution sizing, counting, and phenotyping of individual exosomes down to 50nm without requiring extensive sample purification. A key feature is its microarray-based technology that allows for label-free detection from complex samples like blood, urine, and saliva. Subsequently, the company released the next-generation ExoView R200, which added capabilities such as a near-infrared fluorescence channel, automated sample processing, and higher throughput. The technology also found application in gene therapy with the LentiView platform for characterizing lentiviruses. Following the acquisition by Unchained Labs, the product was relaunched under the brand name Leprechaun.